3 October 2024
Appendix 3H
3 October 2024
Date of Annual General Meeting 2024
16 September 2024
Appendix 3Y
12 September 2024
Starpharma Receives $5.5M R&D Tax Incentive Refund
9 September 2024
Ceasing to be a substantial holder
2 September 2024
Appendix 3Y
2 September 2024
Appendix 3Y
28 August 2024
Appendix 2A
27 August 2024
Change in Substantial Holding
22 August 2024
Starpharma Annual Report and Full-Year Financial Results
30 July 2024
Quarterly Activities Report & Appendix 4C
27 June 2024
Appendix 3Y
27 June 2024
Appendix 3Y
25 June 2024
Change in substantial holding
20 June 2024
Appendix 3Y
12 June 2024
DEP® cabazitaxel presentation at ASCO 2024 Annual Meeting
12 June 2024
DEP® irinotecan presentation at ASCO 2024 Annual Meeting
11 June 2024
Appendix 3G
11 June 2024
DEP presentation at SNMMI
30 May 2024
Appendix 3Y

Investor Relations

For general questions about Starpharma Holdings Limited, please contact us at:

T: +61 3 8532 2700
E: investor.relations@starpharma.com

Important Notice

This website is intended for people seeking information about Starpharma for investment and business purposes. This website contains information about products that may not be available, or approved, in all countries, or may be available under different trademarks, or for different indications. Individuals seeking information about a Starpharma product should visit the relevant product website in their country of residence or consult a healthcare provider. Nothing contained on this site should be considered a solicitation, promotion, or advertisement for any product, including those under development. Any information on this site is not intended to provide medical advice nor should be used as a substitute for the advice provided by a doctor or other healthcare provider.